Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals Limited has announced the quotation of 139,383 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective May 12, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its capital base.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily serves the healthcare sector, offering innovative solutions for cancer treatment and diagnosis.
Average Trading Volume: 1,968,807
Technical Sentiment Signal: Buy
Current Market Cap: A$8.64B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue